View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
January 31, 2022

Aurealis and Xbiome sign licence deal for four-in-one therapy in China

Xbiome will make upfront, commercial and development milestone payments totalling $139m to Aurealis.

Aurealis Therapeutic and Xbiome have signed an exclusive licence and partnership agreement to clinically develop and market the former’s AUP-16 four-in-one therapy in Greater China. 

Free Report
img

2022: So far In Venture Capital

Global investment in 2022 has been majorly dominated by North America, Europe, and Asia Pacific, whereas the Middle East, and South and Central America have recorded low investments comparatively. In light of this, Europe and North America have been identified as the major destinations for Private Equity and Venture Capital (PE/VC) investments.   GlobalData’s whitepaper analyzes which sectors PE/VC firms have been investing in, looking at Technology, Media, and Telecom, with these sectors recording $356 billion and a deal volume of over 10,000 deals in 2022. Healthcare, Financial Services, Business & Consumer Services, and Construction sectors have also seen high investment activity by PE/VC firms, recording a deal value of over $70 billion each.   But what can this mean for you?   Understand how the Deals Database on GlobalData Explorer can be leveraged to:  
  • Track the Aggregate Investment Volumes in PE/VC-Stage firms across geographies and sectors, in addition to viewing the specific deals that drove these volumes
  • Identify the top investors already active in any sector-Geography combinations
  • Assess the Performance of Financial and Legal Advisors, supporting the Dealmaking in any segment of choice (Customizable League tables)
  • Understand what is driving the PE/VC fundraising (Deal Rationale)
  Consult our full report here and optimize your business strategy.
by GlobalData
Enter your details here to receive your free Report.

AUP-16 is an investigational drug candidate for diabetic foot ulcer (DFU), various other chronic wounds and inflammatory diseases.

An all-in-one product that is regarded as one active pharmaceutical ingredient, AUP-16 is a genetically engineered Lactococcus lactis, a non-pathogenic, probiotic bacteria.

It expresses human basic fibroblast growth factor (FGF2, bFGF), interleukin-4 (IL4) and macrophage colony-stimulating factor (CSF1, mCSF).

The therapy is applied topically on chronic wounds such as in DFU, venous leg ulcers and pressure ulcers and is then covered with a wound dressing.

Through the deal, Xbiome attains exclusive development and commercial rights to AUP-16 for all human usage in Mainland China, Macao, Taiwan and Hong Kong.

In these licenced regions, Xbiome will handle all clinical and other development, regulatory submissions and marketing of the licenced products.

Furthermore, outside these territories, Aurealis holds complete rights to AUP-16 and will continue to advance the worldwide development of the drug candidate. 

Aurealis and Xbiome will partner to co-develop the therapy for DFU and other chosen indications. 

Xbiome will make upfront, development milestone payments to Aurealis, which is also entitled to receive commercial milestone payments, under the deal that could total $139m. 

Aurealis will also receive single to double-digit ascending royalty payments based on product sales.

Aurealis Therapeutic CEO Juha Yrj nheikki said: “We are extremely happy to partner with Xbiome. We are impressed by their expertise, agility in execution and commitment to the treatment of diabetes-related diseases and introducing the world’s leading AI microbiome-based treatment methods and drugs into the China market and beyond, of which AUP-16 will be a great example. 

“We believe that this partnership will accelerate the development of AUP-16 as a potential new therapy for DFU and other chronic wound patients.”

Related Companies

Free Report
img

2022: So far In Venture Capital

Global investment in 2022 has been majorly dominated by North America, Europe, and Asia Pacific, whereas the Middle East, and South and Central America have recorded low investments comparatively. In light of this, Europe and North America have been identified as the major destinations for Private Equity and Venture Capital (PE/VC) investments.   GlobalData’s whitepaper analyzes which sectors PE/VC firms have been investing in, looking at Technology, Media, and Telecom, with these sectors recording $356 billion and a deal volume of over 10,000 deals in 2022. Healthcare, Financial Services, Business & Consumer Services, and Construction sectors have also seen high investment activity by PE/VC firms, recording a deal value of over $70 billion each.   But what can this mean for you?   Understand how the Deals Database on GlobalData Explorer can be leveraged to:  
  • Track the Aggregate Investment Volumes in PE/VC-Stage firms across geographies and sectors, in addition to viewing the specific deals that drove these volumes
  • Identify the top investors already active in any sector-Geography combinations
  • Assess the Performance of Financial and Legal Advisors, supporting the Dealmaking in any segment of choice (Customizable League tables)
  • Understand what is driving the PE/VC fundraising (Deal Rationale)
  Consult our full report here and optimize your business strategy.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology